[ad_1] Securities Class Action Pending Over Key Drug’s Efficacy SAN FRANCISCO, Dec. 5, 2025 /PRNewswire/ — Global plaintiffs’ rights law firm Hagens Berman reminds investors of the December 8, 2025, deadline to move the Court for […]
Tag: Hagens Berman Sobol Shapiro LLP
SEC Subpoena & FDA CRL on CMC/Supply Chain
[ad_1] Partner Reed Kathrein Scrutinizes Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO, Dec. 3, 2025 /PRNewswire/ — National shareholder rights law firm Hagens Berman reminds investors […]
Hagens Berman Investigating Accounting Estimate Change and $97M Reserve Issue Driving 33% Plunge
[ad_1] Lead Partner Reed Kathrein: Scrutiny Focuses on Extent of Leadership Awareness Regarding Chronic Payor Denials and Collectability Issues SAN FRANCISCO, Dec. 2, 2025 /PRNewswire/ — Prominent shareholder rights law firm Hagens Berman has opened […]
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% — Hagens Berman
[ad_1] ALVO Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, Dec. 2, 2025 /PRNewswire/ — Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its […]
Hagens Berman Scrutinizing MoonLake’s SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority
[ad_1] Lead Partner Reed Kathrein Investigating Alleged Undisclosed Truth: Did SLK’s Nanobody Structure Truly Confer a Superior Clinical Benefit Over Monoclonal Antibodies? SAN FRANCISCO, Dec. 1, 2025 /PRNewswire/ — Global plaintiffs’ rights law firm Hagens Berman […]
